Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Par Pharma Begins Shipment Of Generic Provigil - Quick Facts

Par Pharmaceutical Companies, Inc. (PRX: Quote) on Friday said it began shipping all strengths of modafinil tablets, a generic version of Teva's Provigil brand. Par's initial shipments will comprise generically-labeled presentations of the Provigil product.

Par acquired the U.S. marketing rights to modafinil from Teva when Teva acquired Cephalon in 2011. According to IMS Health data, annual sales in the U.S. for Provigil are around $1.1 billion.

Modafinil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder.

Modafinil is contraindicated in patients with a known hypersensitivity to modafinil, armodafinil or its inactive ingredients.

Click here to receive FREE breaking news email alerts for Par Pharmaceutical Companies Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Computer and printer maker Hewlett-Packard Co. (HPQ) said Wednesday after the markets closed that its third quarter profit fell 29% from last year, hurt mainly by higher restructuring charges even as revenue grew 1%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue beat analysts' forecast. Stocks fluctuated over the course of the trading day on Wednesday before ending the session mostly higher. The Dow and the S&P 500 both finished the day in positive territory, although the tech-heavy Nasdaq posted a modest loss. President Barack Obama spoke harshly of the terrorist group allegedly responsible for the execution of American freelance journalist James Foley in a statement on Wednesday. Obama described the group known as the Islamic State of Iraq and the Levant, or ISIL, as a cancer that needs to be extracted.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.